(May 24, 2016) NeuroQuest Inc. (www.neuroquest.ca), and its joint-venture partner Concept 2 Clinic Inc. (www.concept2clinic.com) (together, “Company”) today announced that the results from an extensive market research highlight the need for new treatment options for neuropathic pain (NP). Details from the study indicated that currently approved drugs have low efficacy and/or result in severe side effects, especially for orally given drugs, resulting in widespread unmet needs among a large section of patients.
The topical pain market presents an attractive market entry proposition, primarily due to the segment market growth and lower competitive barriers. The topical pain market, a segment of the transdermal drug market, is estimated to grow by 9.7% CAGR, outpacing the global pain market, which is estimated to grow at a CAGR of 3%.
This research has shown that the Company’s lead NP drug candidates, NQ1123 and PN34, in the topical segment, represents strong candidates to overcome many of the current therapeutic limitations of neuropathic pain management primarily due to minimal side effects, strong safety profile, and multi-mechanism mode of action, which not only improves efficacy but could make NQ1123 and PN34 the only multi-mechanism topical drug products on the market.
“Recent publications (See Reference) suggest that pain is a multi-mechanism phenomenon. These observations are consistent with the fact that successfully approved drugs for pain is multi-mechanistic, and there have been numerous failures of pipeline drugs developed with a single mechanism approach.” said Robert Cervelli, NeuroQuest’s Chief Executive Officer. “This market research concluded that, based on historical deals in the topical segment, with our unique multi-mechanism mode of action, NQ1123 and PN34 could command a larger valuation and upfront cash between $10M and $100M USD.”
“PN-34 natural bioactive has minimal toxicity and is classified as Generally Recognized as Safe,
GRAS, as defined by US-FDA. PN34 as a topical product, do not compete with the crowded oral market. In fact, pain treatment plan have increasingly suggested the combination of both topical and oral products, in order to increase their effectiveness“ said YC Lee, Ph.D., Concept 2 Clinic’s Managing Director. “Our formulations were specifically designed and developed to provide both fast acting and long lasting pain relieve effect throughout the day. The Company anticipates initiating a safety/efficacy clinical study with in Q3 2016, with natural product application to Health Canada planned for mid- 2017.”
Reference: Minett, et al 2015: Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium channel Na 1.7, Nature Communications 6, Article number: 8967
NeuroQuest and its joint-venture partner Concept 2 Clinic today announced that the Canadian Intellectual Properties Office (CIPO) and the Korean Intellectual Property Office (KIPO) have issued the patents for the company’s lead natural bioactive products.
“With these issuances in Canada and Korea, we will have very comprehensive intellectual property protection for our lead natural bioactive research programs. We intend to further enhance our intellectual property portfolio with additional patent applications in US, Europe, China and Japan throughout 2016 and beyond,” said Robert Cervelli, NeuroQuest’s Chief Executive Officer.
“Our Company’s medicinal chemistry program began with specific naturally occurring compounds which have prior evidence of efficacy and safety in both animal and human studies. These natural compounds are listed as “GRAS” (Generally Regarded As Safe) by the US FDA, providing an excellent safety profile. PN34 is a naturally-occurring bioactive which is highly efficacious in relieving neuropathic and nociceptive pains. Unlike currently marketed neuropathic pain therapeutics, PN34 has no life-threatening side effects, and induces no numbing or burning sensation. These properties of PN34 appeal to current market needs, which place increasing pressure on drug safety,” said YC Lee, Concept 2 Clinic’s Managing Director.
Canadian Patent Number CA 2676139 “Composition Comprising Terpene Compounds and Methods for Inhibiting Nerve Transmission”, was issued in February, 2016 and will expire in 2028. Korean Patent Number 10-1580857 “Composition Comprising Terpene Compounds and Methods for Inhibiting Nerve Transmission” was issued on December 22, 2015 and will expire in 2028.